102
Participants
Start Date
November 18, 2019
Primary Completion Date
November 4, 2024
Study Completion Date
November 4, 2024
Tazemetostat
Tazemetostat (EPZ-6438) is a selective small-molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
Abiraterone/prednisone
1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily in combination with prednisone 5 mg administered orally twice daily.
Enzalutamide
enzalutamide 160 mg (four 40 mg capsules) orally once daily
Memorial Sloan Kettering Cancer Center, New York
Montefiore Einstein Center for Cancer Care, The Bronx
Associated Medical Professionals of NY, PLLC - Urology, Syracuse
University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie
Urology Associates P.C., Hendersonville
SCRI - Tennessee Oncology Nashville, Nashville
SCRI - Tennessee Oncology Chattanooga, Chattanooga
XCancer - Tennesee Cancer Specialists, Knoxville
XCancer - Northwest Oncology and Hematology, Rolling Meadows
Urology San Antonio, San Antonio
The Urology Center Of Colorado, Denver
Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas
Genesis Healthcare Partners, San Diego
Dana Farber Cancer Institute, Boston
Beth Israel Deaconess Medical Center, Boston
Academisch Ziekenhuis Groeninge Campus Kennedylaan, Kortrijk
Hospital Universitario de Jerez de la Frontera, Jerez de la Frontera
Hospital de la Santa Creu i. Sant Pau, Barcelona
Hospital del Mar Parc de Salut Mar, Barcelona
Hospital Clinico San Carlos, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario La Paz, Madrid
Clinica Universidad de Navarra, Pamplona
Lead Sponsor
Epizyme, Inc.
INDUSTRY